Synexus recruits highest number of patients for successful JUPITER study
02 Apr 2009
Manchester-based Synexus, a global leader in the recruitment of patients to its own research centres, recruited 2,200 of the 17,802 patients who took part in the recent JUPITER trial presented on Monday 30th March at the ACC*and published in the Lancet. It was the most successful source of patient recruitment providing 13% of participants to just 1% of the 1315 sites taking part in the study.
Commenting on Synexus role in the JUPITER trial, Michael Fort, CEO said: "Our success in recruiting patients quickly and efficiently is increasingly well known across a range of therapies. With JUPITER we have also been able to demonstrate, very clearly, just how cost effective our methods, in particular slashing monitoring costs, Of the 2,200 patients we enrolled only two failed to complete the study and that's another achievement in terms of the quality of patients we are able to deliver for our clients."
*ACC The American College of Cardiology
If you would like an assessment on a clinical trial please send us your details and we will get back to you.
Have more questions? Contact us for more information
